Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Rib-X Pharmaceuticals, Inc. has initiated a Phase 3 clinical trial of a Captisol-enabled™ intravenous (IV) formulation of ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the first quarter ended March 31, 2013, and provided an operating forecast and program updates. ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has acquired a portfolio of potential future milestone and royalty payments for more than 15 biologic development programs from Selexis SA. Each acquired ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer of Ligand, is scheduled to present at the following upcoming investor ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2013 financial results on Wednesday, May 8, 2013. Ligand’s President and CEO, John Higgins, Executive Vice ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of global license and supply agreements with Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) for the development and ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces receipt of a $1.4 million milestone payment from Retrophin, Inc. (OTCQB: RTRX) under the terms of a license agreement signed in February ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced financial results for the three and 12 months ended December 31, 2012 and reviewed business highlights for the fourth quarter of ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter 2012 financial results on Wednesday, February 13, 2013. Ligand’s President and CEO, John L. ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has received a milestone payment of 620,000 shares of common stock in newly public partner Retrophin, Inc. (OTCQB: RTRX). ... read more

Pfizer Inc. (NYSE: PFE) and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has initiated a pivotal trial of Captisol-enabled®, propylene glycol-free (PG-free) high-dose melphalan as a conditioning ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will be providing a detailed review of its business model and growth strategy, along with introducing financial guidance for 2013 and 2014, during ... read more

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day in New York City on Tuesday, December 4, 2012 from 10:15 a.m. to 12:00 p.m. Eastern Time (7:15 ... read more